Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series

Manish Suthar, Saniya Gupta, Suhail Bukhari, Venkatesh Ponemone, Manish Suthar, Saniya Gupta, Suhail Bukhari, Venkatesh Ponemone

Abstract

Background: Non-healing ulcers are a major health problem worldwide and have great impact at personal, professional and social levels, with high cost in terms of human and material resources. Recalcitrant non-healing ulcers are inevitable and detrimental to the lower limb and are a major cause of non-traumatic lower limb amputations. Application of autologous Platelet Rich Plasma (PRP) has been a major breakthrough for the treatment of non-healing and diabetic foot ulcers, as it is an easy and cost-effective method, and provides the necessary growth factors that enhance tissue healing. PRP is a conglomeration of thrombocytes, cytokines and various growth factors which are secreted by α-granules of platelets that augment the rate of natural healing process with decrease in time. The purpose of this case series was to evaluate the safety and efficacy of autologous platelet rich plasma for the treatment of chronic non-healing ulcers on the lower extremity.

Methods: Autologous PRP was prepared from whole blood utilizing a rapid, intraoperative point-of-care system that works on the principle of density gradient centrifugation. Twenty Four (24) patients with non-healing ulcers of different etiologies, who met the inclusion criteria, were treated with single dose of subcutaneous PRP injections along with topical application of PRP gel under compassionate use.

Results: The mean age of the treated patients was 62.5 ± 13.53 years and they were followed-up for a period of 24 weeks. All the patients showed signs of wound healing with reduction in wound size, and the mean time duration to ulcer healing was 8.2 weeks. Also, an average five fold increase in the platelet concentrate was observed in the final PRP product obtained using the rapid point-of-care device, and the average platelet dose administered to the patients was 70.10 × 108.

Conclusion: This case series has demonstrated the potential safety and efficacy of autologous platelet rich plasma for the treatment of chronic non-healing ulcers.

Trial registration: NCT03026855 , Registered 4 January 2017 'Retrospectively'.

Keywords: Autologous platelet rich plasma; Cellular therapy; Cytokines; Growth factors; Non-healing ulcers; Point-of-care.

Figures

Fig. 1
Fig. 1
Distribution of cumulative ulcer healing time following PRP treatment
Fig. 2
Fig. 2
Distribution of Platelet counts at pre- and post- processing (*p < 0.05)
Fig. 3
Fig. 3
Distribution of Reduction in RBC content in Pre- and Post-processed PRP (*p < 0.05)
Fig. 4
Fig. 4
Distribution of WBC counts in pre- and post- processed PRP
Fig. 5
Fig. 5
Patient follow-up images depicting the treatment efficacy of PRP during follow-up period

References

    1. Sebastian KMS, Lobato I, Hernandez I, et al. Efficacy and safety of autologous platelet rich plasma for the treatment of vascular ulcers in primary care: phase III study. BMC Fam Pract. 2014;15:211. doi: 10.1186/s12875-014-0211-8.
    1. Greer N, Foman N, Dorrian J, et al. Advanced wound care therapies for non-healing diabetic, venous, and arterial ulcers: a systematic review. 2012.
    1. Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Autologous platelet rich plasma for treating chronic wounds. Cochrane Database Syst Rev. 2012;Issue 10:Art. No.: CD006899.
    1. Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. Adv Wound Care. 2015;4(9):560–82. doi: 10.1089/wound.2015.0635.
    1. Rayner R, Carville K, Keaton J, et al. Leg ulcers: atypical presentations and associated co-morbidities. Wound Pract Res. 2009;17(4):168–85.
    1. Agale SV. Chronic leg ulcers: epidemiology, aetiopathogenesis, and management. Ulcers. 2013;Article ID 413604:9.
    1. Suresh DH, Suryanarayan S, Sarvainamurthy S, et al. Treatment of a Non-healing diabetic foot ulcer with platelet rich plasma. J Cutan Aesthet Surg. 2014;7(4):229–31. doi: 10.4103/0974-2077.150786.
    1. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117:1219–22. doi: 10.1172/JCI32169.
    1. Anderson I. Aetiology, assessment and management of leg ulcers. Wound Essent. 2006;1:20–36.
    1. Suryanarayan S, Budamakuntla L, Khadri SIS, et al. Efficacy of autologous platelet-rich plasma in the treatment of chronic non-healing leg ulcers. Plast Aesthet Res. 2015;1(2):65–9. doi: 10.4103/2347-9264.139703.
    1. Aminian B, Shams M, Karim-Aghaee B, Soveyd M, Omrani GR. The role of the autologous platelet-derived growth factor in the management of decubitus ulcer. Arch Iranian Med. 1999;2:98–101.
    1. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg. 1995;21(1):71–81. doi: 10.1016/S0741-5214(95)70245-8.
    1. Driver R, Hanft J, Fylling P, et al. A prospective, randomized, controlled trial of autologous platelet rich plasma for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52(6):68–87.
    1. Damir A. Recent advances in management of chronic non-healing diabetic foot ulcers. JIMSA. 2011;24(4):219–23.
    1. Andia I, Abate M. Platelet-rich plasma: underlying biology and clinical correlates. Regen Med. 2013;8(5):645–58. doi: 10.2217/rme.13.59.
    1. Obolenskiy VN, Ermolova DA, Laberko LA, Semenova TV. Efficacy of platelet rich plasma for the treatment of chronic wounds. EWMA J. 2014;14(1):37–41.
    1. Anitua E, Aguirre JJ, Algorta J, et al. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res Appl Biomater. 2008;84(2):415–21. doi: 10.1002/jbm.b.30886.
    1. Borzini P, Mazzucco L. Platelet gels and releasates. Curr Opin Hematol. 2005;12(6):473–9. doi: 10.1097/01.moh.0000177831.70657.e8.
    1. Su CY, Kuo YP, Nieh HL, et al. Quantitative assessment of the kinetics of growth factors released from platelet gel. Transfusion. 2008;48(11):2414–20. doi: 10.1111/j.1537-2995.2008.01862.x.
    1. Nurden AT, Nurden P, Sanchez M, et al. Platelets and wound healing. Front Biosci. 2008;13(9):3532–48.
    1. Lacci MK, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med. 2010;83(1):1–9.
    1. Carter MJ, Fylling CP, Parnell LK. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty. 2011;11:e38.
    1. Tzeng YS, Deng SC, Wang CH, et al. Treatment of nonhealing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a case series. Biotechnol Res Int. 2013;Article ID 837620:9.
    1. Sunitha RV, Munirathnam NE. Platelet rich fibrin: evolution of a second generation platelet concentrate. Indian J Dent Res. 2008;19(1):42–6. doi: 10.4103/0970-9290.38931.
    1. Crawford F, Inkster M, Kleijnen J, Fahey T. Predicting foot ulcers in patients with diabetes: a systematic review and meta-analysis. QJM. 2007;100(2):65–86. doi: 10.1093/qjmed/hcl140.
    1. Knighton DR, Ciresi KF, Fiegel VD, et al. Classification and treatment of chronic nonhealing wounds: Successful treatment with autologous platelet-derived wound healing factors (PDWHF) Ann Surg. 1986;204:322–30. doi: 10.1097/00000658-198609000-00011.
    1. Martin P. Wound healing - aiming for perfect skin regeneration. Science. 1997;276:75–81. doi: 10.1126/science.276.5309.75.
    1. Kakudo N, Kushida S, Ogura N, Hara T, Suzuki K. The use of autologous platelet rich plasma in the treatment of intractable skin ulcer. Open J Reg Med. 2012;1:29–32.
    1. Everts PA, BrownMahoney C, Hoffmann JJ, et al. Platelet-rich plasma preparation using three devices: implications for platelet activation and platelet growth factor release. Growth Factors. 2006;24:165e71. doi: 10.1080/08977190600821327.
    1. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10:225e8. doi: 10.1097/00008505-200110000-00002.
    1. Kevy SV, Jacobson MS. Preparation of growth factor enriched autologous platelet gel. Presented at the 27th Annual Meeting of the Society for Biomaterials: St. Paul, MN. 2001.
    1. Mehrannia M, Vaezi M, Yousefshahi F, et al. Platelet rich plasma for the treatment of non-healing diabetic foot ulcer: a case series. Can J Diabetes. 2014;38:5–8. doi: 10.1016/j.jcjd.2013.08.271.
    1. Singh RP, Marwaha N, Malhotra P, Dash S. Quality assessment of platelet concentrates prepared by platelet rich plasma platelet concentrate, buffy coat poor platelet concentrate (BCPC) and apheresis PC methods. Asian J Transfus Sci. 2009;3:86–94. doi: 10.4103/0973-6247.53882.
    1. Sánchez AR, Sheridan PJ, Kupp LI. Is platelet-rich plasma the perfect enhancement factor? A current review. Int J Oral Maxillofac Implants. 2003;18:93–103.
    1. Frykberg RG, Driver VR, Carman D, et al. Chronic wounds treated with a physiologically relevant concentration of platelet-rich plasma gel: a prospective case series. Ostomy Wound Manage. 2010;56:36–44.
    1. Steenvoorde P, van Doorn LP, Naves C, Oskam J. Use of autologous platelet rich fibrin on hard-to-heal wounds. J Wound Care. 2008;17:60–3. doi: 10.12968/jowc.2008.17.2.28179.
    1. Mehta S, Watson JT. Platelet rich concentrate: basic science and current clinical applications. J Orthop Trauma. 2008;22(6):432–8. doi: 10.1097/BOT.0b013e31817e793f.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel